Citius Oncology, Inc. Stock Analysis & AI Score
Citius Oncology, Inc. (CTOR) has an ST Score of 38.4 (C), driven by its Forecast (A) and held back by its Financial Strength (F). Analysts rate it Buy with a $6.00 price target (+471.4% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Medical - Pharmaceuticals |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Citius Oncology, Inc. (CTOR) has an ST Score of 38.4 (C), driven by its Forecast (A) and held back by its Financial Strength (F). Analysts rate it Buy with a $6.00 price target (+471.4% upside).
- Strongest
- ForecastA
- Weakest
- Financial StrengthF
All factor grades
- ForecastA
- MomentumB-
- ValuationC+
- GrowthC-
- ProfitabilityD-
- Financial StrengthF
- Piotroski3/9
Contact
CTOR stock: frequently asked questions
What is CTOR's ST Score?
Citius Oncology, Inc. (CTOR) has an ST Score of 38.4 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is CTOR a buy, hold, or sell?
Analysts rate CTOR a Buy, with a price target of $6.00 (+471.4% vs the current price). Our ST Score grades it C (38.4/100). The ST Score is a data-driven signal, not a recommendation.
What are CTOR's factor grades?
Valuation C+, Profitability D-, Financial Strength F, Momentum B-, Growth C-, Forecast A.
What is CTOR's valuation grade?
Citius Oncology, Inc. (CTOR) earns a valuation grade of C+, measured against Medical - Pharmaceuticals peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is CTOR's growth grade?
Citius Oncology, Inc. (CTOR) earns a growth grade of C-, measured against Medical - Pharmaceuticals peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is CTOR's profitability grade?
Citius Oncology, Inc. (CTOR) earns a profitability grade of D-, measured against Medical - Pharmaceuticals peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is CTOR's financial strength grade?
Citius Oncology, Inc. (CTOR) earns a financial strength grade of F, measured against Medical - Pharmaceuticals peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for CTOR?
The average analyst price target for Citius Oncology, Inc. (CTOR) is $6.00 from 2 analysts, which is +471.4% versus the recent price of $1.05.
What is CTOR's Piotroski score?
Citius Oncology, Inc. (CTOR) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.